Back to results
US 12,631,644 B2Granted
Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
AssigneeArterez, Inc.
InventorJosefino B. Tunac
Life of this patent
Estimating the term…
Abstract
The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.
Claims21
A method of treating a subject having a disease characterized by a disruption of a glycocalyx, the method comprising:
- administering to the subject a composition of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or Formula XI:
- wherein the subject has been previously identified as having the disease characterized by the disruption of the glycocalyx by measuring at least three biomarkers selected from the group consisting of gamma fibrinogen (GF), growth differentiation factor 15 (GDF-15), and pregnancy-associated plasma protein (PAPP-A).
A method comprising:
- obtaining a biological sample from a subject;
- measuring a level of each biomarker of at least three biomarkers in the biological sample, wherein each biomarker of the at least three biomarkers is selected from the group consisting of gamma fibrinogen (GF), growth differentiation factor 15 (GDF-15), and pregnancy-associated plasma protein (PAPP-A);
- and
- administering to the subject a composition of Formula I, Formula II, Formula II, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or Formula XI:
1 more element
A method of treating a subject identified as having coronary heart disease (CHD), hypertension (HTN), or heart failure (HF), the method comprising:
- obtaining a blood sample from a subject;
- measuring a level of each biomarker of at least three biomarkers in the blood sample, wherein each biomarker of the at least three biomarkers is selected from the group consisting of gamma fibrinogen (GF), growth differentiation factor 15 (GDF-15), and pregnancy-associated plasma protein (PAPP-A);
- determining the subject as having the CHD, the HTN, or the HF by detecting a biological signature indicative of the CHD, the HTN, or the HF from the level of each biomarker of the at least three biomarkers;
- and
- treating the subject for the CHD, the HTN, or the HF by administering to the subject a composition of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or Formula XI:
2 more elements
Dependencies are inferred from the claim text.